上海国资，买了一家上市公司

Core Viewpoint - The article highlights the increasing activity in the merger and acquisition (M&A) market in China, particularly driven by state-owned capital and the establishment of various acquisition funds targeting listed companies [3][4][11]. Group 1: M&A Market Dynamics - Since the beginning of the year, the M&A market has seen significant activity, with various regions like Shanghai, Beijing, and Guangzhou setting up industrial acquisition funds to integrate supply chains and cultivate industry leaders [3][9]. - The Shanghai Biopharmaceutical Industry M&A Fund, established in March 2023 with a scale of 5.01 billion yuan, is a key player in this trend, backed by a strong consortium of state-owned and private enterprises [7][9]. Group 2: Notable Transactions - On July 20, 2023, Kanghua Biotech announced a significant transaction involving the transfer of 28.47 million shares (21.91% of total shares) to Shanghai Wankexin Biotechnology, marking the first acquisition deal for the Shanghai Biopharmaceutical Industry M&A Fund [5][6]. - Following the share transfer, Wankexin will hold 29.99% of the voting rights, effectively changing the controlling shareholder from Wang Zhentao to Wankexin, which will have no actual controller [6][7]. Group 3: Policy and Future Outlook - The Shanghai government has launched initiatives to support M&A activities, including a 10 billion yuan biopharmaceutical industry fund aimed at fostering innovation and restructuring in the sector [9][12]. - The current market environment is seen as a historic opportunity for M&A funds, with expectations of increased activity in the second half of 2023 due to favorable policies and a growing appetite for acquisitions among listed companies [12][14].